Genotypes, Fluconazole Tolerance and Virulence Phenotypes of Candida albicans Bloodstream Isolates: A Multilocus Sequence Typing‐Based Analysis Authors: Shang‐Yi Lin, Yin‐Tse Huang, Ho‐Yin Huang, Wei‐Chun Hung, Yi‐Ting Tseng, Po‐Liang Lu Published: 2026 ABSTRACT ABSTRACTBackgroundFluconazole tolerance is an emerging phenotype in Candida albicans bloodstream infections, but its relationship to multilocus sequence typing (MLST) lineages and virulence traits is unclear.ObjectivesTo investigate the relationships among MLST genotypes, fluconazole tolerance, and virulence phenotypes in C. albicans bloodstream isolates.Methods179 C. albicans bloodstream isolates collected from three hospitals in southern Taiwan (2013–2020) were evaluated. Fluconazole tolerance was quantified as the fraction of growth within the inhibition zone (FoG20) using the diskImageR pipeline. Phenotypic profiling included quantification of biofilm biomass and extracellular hydrolytic enzymes. Genetic relatedness was determined via MLST.ResultsThe cohort exhibited significant fluconazole tolerance with a mean FoG20 of 0.29 ± 0.19. FoG20 weakly correlated with biofilm biomass (r = 0.218, p = 0.003). MLST identified 169 unique diploid sequence types with 14 clades and 25 clonal complexes (CCs). The high fluconazole tolerance phenotype was broadly distributed across genetically diverse lineages, although clade 16 showed higher mean FoG20 (0.39) (p = 0.003) and biofilm biomass (0.83) (p = 0.039). In multivariable analysis, clade 16 (aOR 2.86; 95% CI 1.08–7.56; p = 0.034) and protease activity (aOR 2.65; 95% CI 1.24–5.64; p = 0.012), but not biofilm biomass (p = 0.142), were independently associated with high tolerance. High tolerance showed a borderline association with 14‐day mortality (aOR 2.56; 95% CI 0.99–6.62; p = 0.052).ConclusionsFluconazole tolerance in C. albicans was distributed across diverse lineages, suggesting convergent adaptation. Clade 16 and protease activity were independently associated with tolerance. Given the observed trend toward an association between high tolerance and 14‐day mortality, future mechanistic studies and larger clinical outcome studies are warranted. Introduction Candida albicans is a common constituent of the human commensal flora. However, it remains the leading cause of candidemia, particularly in immunocompromised and critically ill patients [1, 2]. Recognizing its substantial disease burden and virulence potential, the World Health Organization categorized C. albicans as a ‘critical priority pathogen’ in its 2022 fungal priority pathogens list [3]. Fluconazole remains a cornerstone in the management of candidemia, especially as step‐down therapy for hemodynamically stable patients with susceptible isolates following initial echinocandin treatment [1, 4]. Current guidelines recommend routine azole susceptibility testing for all clinically significant Candida bloodstream isolates [1, 4, 5]. Despite in vitro susceptibility, clinical failure of fluconazole therapy for C. albicans infections is not uncommon [2, 6, 7]. This suggests that the frequency of treatment failure often exceeds the reported rates of resistance, although fluconazole resistance is relatively rare in C. albicans . Thus, clinical outcomes may be influenced by microbiological features not captured by standard antifungal susceptibility testing (AST) [7, 8]. One such phenomenon is fluconazole tolerance, which is defined as reduced yet persistent growth at drug concentrations exceeding the minimum inhibitory concentration (MIC) [6, 9, 10]. Unlike antifungal resistance, which is defined by a reproducible and stable increase in baseline MIC and is typically driven by genetic alterations such as ERG11 mutations or efflux‐pump upregulation, tolerance is phenotypically manifested as trailing growth and reflects phenotypic or epigenetic plasticity mediated by stress‐response pathways (e.g., Hsp90 and calcineurin) [7, 8]. Trailing growth does not increase the MIC and is typically detectable only after prolonged incubation (≥ 48 h), beyond the timeframe of routine clinical susceptibility testing [2, 7, 11]. It also differs from heteroresistance, which involves the rapid selection of a minor, intrinsically resistant subpopulation (< 1%) often via temporary aneuploidy, loss of heterozygosity, or chromosomal rearrangements [8, 12]. While the emergence of multidrug‐resistant (MDR) Candida species, most notably C. auris and C. glabrata , has posed a severe global health threat, the clinical prevalence of true MDR phenotypes remains extraordinarily rare among C. albicans isolates, typically accounting for less than 1% of cases in large‐scale international surveillance programs [13, 14, 15]. Consequently, instead of genetic MDR, non‐classical drug responses such as fluconazole tolerance may be the hidden microbiological driver compromising clinical success in C. albicans infections. Although this phenotype remains unrecognized in standard laboratory workflows, our previous findings demonstrated that a heavy trailing effect was significantly associated with persistent candidemia [2], highlighting the need to further characterize this tolerance phenotype and its biological determinants. However, whether fluconazole tolerance is linked to the specific genetic background of C. albicans remains unclear. Multilocus sequence typing (MLST) has been widely used to investigate the population structure, clonal relatedness, and epidemiological patterns of C. albicans isolates [16, 17, 18, 19, 20]. Certain MLST clades have been associated with antifungal resistance, geographic distribution, and host adaptation; however, their relationship with antifungal tolerance phenotypes such as trailing growth has not been explored [21, 22, 23]. Furthermore, C. albicans virulence is mediated by multiple factors, including secreted hydrolytic enzymes (e.g., phospholipases and secreted aspartyl proteinases) and biofilm formation, all of which contribute to tissue invasion, immune evasion, and persistence during infection [24]. Although these virulence determinants are well‐characterized, their potential interaction with fluconazole tolerance remains unclear. Thus, whether isolates exhibiting high tolerance also display enhanced virulence traits or whether tolerance and virulence are co‐segregated within specific MLST genotypes is unknown. Therefore, we aimed to investigate the relationships among MLST genotypes, fluconazole tolerance, and key virulence factors, including biofilm formation and extracellular hydrolytic enzymes, in C. albicans bloodstream isolates. Materials and Methods Candida albicans Isolates A total of 179 C. albicans bloodstream isolates were collected from three hospitals in southern Taiwan (one medical center and two regional hospitals) between January 2013 and December 2020. These isolates were primarily derived from a previously published cohort used to evaluate fluconazole tolerance [2]. The inclusion criteria were as follows: (i) adult patients (≥ 20 years) presenting with clinical symptoms or signs of sepsis; (ii) at least one blood culture positive for C. albicans ; and (iii) receipt of fluconazole as antifungal monotherapy for a minimum of 48 h. For patients with recurrent infections, only the first episode of candidemia was included in the analysis. This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB‐E(II)‐20250021). Fluconazole Susceptibility and Tolerance Assay Fluconazole MICs were determined by broth microdilution according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference method (E.Def 7.3.1). The MIC was defined as the lowest drug concentration causing ≥ 50% inhibition of growth relative to the drug‐free control, determined spectrophotometrically at 530 nm. Isolates with fluconazole MICs ≤ 2 mg/L were classified as susceptible [25]. Fluconazole tolerance was assessed using a modified disk diffusion assay, as previously described [6, 7]. Briefly, isolates were subcultured from glycerol stocks onto YPD agar (10 g/L yeast extract, 20 g/L peptone, 20 g/L d‐glucose, 20 g/L agar) and incubated for 24 h at 30°C. Colonies were suspended in 1 mL PBS and diluted to 1 × 106 cells/mL. A total of 2 × 105 cells were plated onto 15 mL 2% YPD agar. A 25‐μg fluconazole disk was placed at the center of the plate, and plates were incubated at 30°C for 48 h. Images were captured and analysed using the diskImageR pipeline. Fluconazole tolerance was quantified as the fraction of growth (FoG) within the inhibition zone and expressed as the area under the growth curve at a defined radius, normalized to the growth outside the zone. FoG20, defined as the FoG within a zone of 20% growth inhibition, was used as the primary tolerance metric [6, 7]. All measurements were performed in triplicate for each isolate by a single trained reader; the final reported value was either the most representative of the three replicates based on image quality, or the average of the remaining two replicates after excluding a discordant reading attributable to an identifiable technical artefact. Several internal controls confirmed the stability of the assay: incubating the fluconazole disk on the agar plate for 24 h prior to inoculation with C. albicans did not alter FoG levels, and performing the assay with or without disk replacement after 24 h of incubation likewise did not change FoG measurements, confirming that drug diffusion and disk stability did not contribute to assay variability [7]. To optimize statistical power and avoid multi‐comparison inflation, the FoG20 was dichotomized into two groups: high fluconazole tolerance (defined as the highest quartile, Q4; FoG20 > 0.42) and non‐high fluconazole tolerance (combined Q1–Q3; FoG20 ≤ 0.42). Biofilm and Extracellular Enzyme Assays Biofilm biomass was quantified by crystal violet staining as previously described. Briefly, isolates were cultured in 96‐well polystyrene plates under standardized conditions, and stained with 0.4% crystal violet. Optical density was measured at 590 nm using a microplate reader [26, 27]. The activities of five extracellular hydrolytic enzymes were assessed using established plate‐based methods. Phospholipase activity was evaluated on egg yolk agar, with enzymatic activity quantified as the precipitation zone ratio: the ratio of colony diameter to the total diameter of the colony plus surrounding precipitation zone, where lower values indicate higher activity [28, 29]. Secreted proteinase activity was assessed using skim milk agar. Plates were incubated at 30°C for 72 h, and protease activity was evaluated qualitatively based on the presence or absence of a clear halo surrounding the colonies; isolates exhibiting a halo were considered protease‐positive [30]. Hemolytic activity was examined on Sabouraud dextrose agar (SDA) supplemented with 7% human blood and 3% glucose; plates were incubated at 37°C for 48 h, and the presence of a translucent halo around colonies was recorded as hemolysis‐positive [31]. Esterase activity was assessed on tryptic soy agar supplemented with 1% Tween 80; plates were incubated at 30°C for up to 72 h and examined daily for precipitation halos, the presence of which was recorded as esterase‐positive [32]. DNase activity was assessed by observing clear zones on DNase methyl green agar after incubation at 37°C for 7 days [33]. Protease, hemolytic, esterase, and DNase activities were assessed qualitatively as the presence or absence of a visible clear or translucent halo around the colony, following established scoring conventions [30, 31, 32, 33]. Unlike phospholipase activity, for which a validated continuous precipitation zone ratio has been established [28], no comparably validated quantitative scoring system exists for these halo‐based assays; isolates were therefore classified as positive if any visible zone was observed after the specified incubation period, consistent with prior literature. All biofilm and extracellular enzyme assays were performed in triplicate (three independent biological replicates) for each isolate; for qualitative assays, the majority result (≥ 2 of 3 replicates) was used to assign the final phenotype call. MLST and Phylogenetic Analysis MLST was performed using a consensus seven‐locus scheme as previously described [34]. Briefly, genomic DNA was extracted, and internal fragments of seven housekeeping genes (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13 and ZWF1b) were amplified using polymerase chain reaction and sequenced. Allele numbers were assigned by comparison with reference sequences from the C. albicans MLST database (http://calbicans.mlst.net/). Novel sequences that did not match any of the existing entries were submitted as new alleles. The combination of allele numbers at seven loci defined a unique diploid sequence type (DST) for each isolate. For phylogenetic analysis, the sequence of each housekeeping gene was aligned against the corresponding reference sequence using MUSCLE in MEGA version 12.0 to identify polymorphic bases. The seven aligned sequences from each isolate were then concatenated into a single composite sequence, with each base position encoded as a two‐letter code representing the homozygous or heterozygous diploid genotype at that site, following previously established methodology for diploid MLST data [17, 34]. Phylogenetic relationships among isolates were then inferred from these transformed sequences using the unweighted pair group method with arithmetic mean (UPGMA) based on the p‐distance with pairwise deletion, implemented in MEGA version 12.0. Clustering robustness was assessed by bootstrap analysis with 1000 replications [17, 35, 36]. Clades were assigned according to previously published classification schemes [17, 36, 37]. The clonal complex (CC) structure was determined by eBURST analysis using the default group definition of sharing six of seven alleles [17, 18, 19, 20]. Clinical Outcome Analysis Complete clinical data were available for 169 adult patients, and the primary clinical endpoints were defined as 14‐day crude mortality and persistent candidemia (defined as a blood culture remaining positive for C. albicans for ≥ 5 days despite active antifungal therapy). Variables included in the univariable and multivariable analyses were selected based on our previous study [2]. Statistical Analysis All statistical analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY, USA). Categorical variables were compared using the chi‐squared test or Fisher's exact test, as appropriate. Continuous variables were compared using Student's t‐test or one‐way analysis of variance. Non‐normally distributed data were analysed using the Mann–Whitney U test (two groups) or the Kruskal–Wallis H test (three or more groups); pairwise post hoc comparisons were performed with Holm adjustment for multiple comparisons. The association between fluconazole tolerance (FoG20) and biofilm formation was evaluated using Pearson's correlation coefficient. Variables yielding a p value of < 0.05 in univariable analysis were included in the multivariable logistic regression model to identify the factors significantly associated with clinical outcome. All statistical tests were two‐sided, and significance was set at p < 0.05. Results Fluconazole Susceptibility and Quantification of Tolerance A total of 179 C. albicans clinical isolates were evaluated for fluconazole susceptibility and tolerance. The fluconazole MIC values in the majority of isolates were ≤ 2 mg/L; only one exhibited an MIC of 16 mg/L. A prominent fluconazole tolerance phenotype was observed during the collection period. Using the diskImageR computational framework, the mean FoG20 value for the entire cohort was 0.29 ± 0.19 (Range: 0.04–0.91). The distribution of the FoG20 values is shown in Figure 1. Distribution of fluconazole tolerance among 179 clinical isolates of Candida albicans . The histogram bars represent the relative density of isolates across the FoG20 value range (0–1.0). The black solid line indicates the kernel density estimation, illustrating the continuous phenotypic variation in fluconazole tolerance. The red dotted line and blue dashed line denote the mean and median FoG20 values, respectively. Association Between Fluconazole Tolerance and Biofilm Formation The biofilm biomass, measured by crystal violet staining, had an optical density (OD) range of 0.17 to 1.67, with a mean OD of 0.59 ± 0.36. A weak but statistically significant positive correlation was observed between FoG20 and biofilm biomass across the entire cohort (r = 0.218, p = 0.003; Figure 2A), indicating that biofilm biomass accounts for only a small proportion of the variance in FoG20 (r 2 ≈0.047). When isolates were stratified into FoG20 quartiles (Q1–Q4, defined based on the cohort distribution as < 0.14, 0.14–0.25, 0.26–0.42, and > 0.42, respectively), isolates in the highest quartile (Q4) (high‐tolerance group) exhibited significantly greater biofilm biomass than those in the three lower quartiles (Q4 vs. Q1–Q3; p = 0.037; Figure 2B). Association between fluconazole tolerance and biofilm formation among 179 Candida albicans bloodstream isolates. (A) Scatter plot showing the correlation between FoG20 and biofilm biomass measured by crystal violet staining (optical density, OD). Each data point represents an individual isolate (r = 0.218, p = 0.003). (B) Box plots showing biofilm biomass (OD) stratified by FoG20 quartile. The horizontal line within each box represents the median; the lower and upper boundaries of the box represent the first (Q1) and third (Q3) quartiles, respectively; whiskers extend to the minimum and maximum values. Individual isolates are overlaid as jittered data points. Isolates in the highest FoG20 quartile (Q4) exhibited significantly greater biofilm biomass compared with those in the lower three quartiles combined (Q4 vs. Q1–Q3; p = 0.037, Mann–Whitney U test). Prevalence and Tolerance‐Stratified Distribution of Extracellular Virulence Factors The C. albicans isolates displayed diverse profiles of extracellular enzymatic activity (Table 1). Esterase activity was the most prevalent trait, detected in 135 isolates (75.4%), followed by hemolytic (β‐hemolysis) activity in 100 isolates (55.9%), DNase activity in 58 isolates (32.8%) and protease activity in 52 isolates (29.1%). The mean phospholipase activity ratio was 0.81 ± 0.13 (lower values indicate higher enzymatic activity). TABLE 1Prevalence of virulence‐associated phenotypes in 179 C. albicans clinical isolates.Virulence factorPrevalence (%)FoG20 Q1–Q3 (n = 138)Q4 (n = 41) p valueProtease52 (29.1)33 (23.9)19 (46.3)0.005Phospholipase (mean ± SD)0.81 ± 0.130.81 ± 0.130.81 ± 0.110.943Esterase135 (75.4)105 (76.1)30 (73.2)0.703DNase58 (32.8)41 (29.7)17 (41.5)0.158Hemolysis (β)100 (55.9)72 (52.2)28 (68.3)0.068 Note: Phospholipase activity is expressed as the precipitation zone ratio (colony diameter/[colony + precipitation zone diameter]); lower values indicate higher enzymatic activity [28]. Prevalence of virulence‐associated phenotypes in 179 C. albicans clinical isolates. Note: Phospholipase activity is expressed as the precipitation zone ratio (colony diameter/[colony + precipitation zone diameter]); lower values indicate higher enzymatic activity [28]. To investigate the relationship between these virulence factors and fluconazole tolerance, the isolates were classified as groups of high‐tolerance (Q4) and non‐high‐tolerance (Q1‐Q3) based on their FoG20 quartiles. The prevalence of protease activity in the high tolerance group (46.3%) was higher than that in the non‐high‐tolerance group (23.9%) (p = 0.005). Hemolytic activity tended to be more prevalent in the high tolerance group (68.3%) compared with the Q1–Q3 group (52.2%), although this difference did not reach statistical significance (p = 0.068). MLST Genotyping, Population Diversity and Clonal Complex Assignment Of 179 C. albicans clinical isolates, 169 unique DSTs were identified. Of these, 141 (78.8%) were assigned to 139 previously unreported DSTs. Most DSTs were represented by single isolates, reflecting a highly diverse population. Among the few shared DSTs, DST 1608 was the most prevalent and was observed in five isolates (2.8%) (Table S1). Phylogenetic analysis assigned the 179 isolates to 14 established MLST clades (Figure 3). The seven most prevalent clades (n > 5) were clade 1 (32 isolates, 17.9%), clade 3 (29 isolates, 16.2%), clade 4 (29 isolates, 16.2%), clade 16 (23 isolates, 12.8%), clade 17 (20 isolates, 11.2%), clade 18 (9 isolates, 5.0%) and clade 14 (7 isolates, 3.9%). Phylogenetic relationships of Candida albicans isolates based on multilocus sequence typing (MLST). UPGMA dendrogram showing the genetic relationships among 179 clinical C. albicans isolates from the present study together with reference isolates (n = 1000) retrieved from the international MLST database. The tree was constructed using UPGMA based on concatenated sequences of the seven MLST housekeeping loci. Isolates were assigned to established MLST clades according to previously defined clade classifications. Coloured outer segments indicate the major clades (clades 1–18), as labelled. Each branch represents an individual isolate, and clustering patterns illustrate the phylogenetic structure of the C. albicans population analysed in this study. Clades 2, 5, 6 and 13 contained no KMUH isolates. Red circles represent KMUH isolates. eBURST analysis identified 25 clonal complexes (CCs). Seventy‐seven isolates (43.0%) were assigned to nine CCs (CC0, CC7, CC10, CC11, CC12, CC22, CC39, CC52 and CC76) (Table S2). The remaining isolates were classified as singletons, reflecting the high genetic diversity of this collection. The correspondence between the UPGMA phylogenetic clade assignment and eBURST CC classification is summarized in Table 2. Clade 16 was predominantly composed of CC11 isolates (16/23 isolates; 69.6%), whereas clade 4 was largely composed of CC7 (24/29 isolates; 82.8%). By contrast, clade 1 exhibited the highest clonal diversity, encompassing multiple CCs, including CC0, CC13, CC26, CC39, CC105, CC208 and CC210. Clade 3 was primarily composed of isolates from CC22 and CC76, whereas clade 17 mainly comprised isolates from CC12. TABLE 2Correlation between UPGMA grouping and eBURST clustering of C. albicans isolates.UPGMA clade (No. of isolates)eBURST clonal complex (no. of isolates)Clade 1 (32)CC0 (5), CC13 (3), CC26 (2), CC39 (6), CC105 (1), CC208 (1), CC210 (2), singleton (12)Clade 2 (0)—Clade 3 (29)CC22 (5), CC76 (4), singleton (20)Clade 4 (29)CC7 (24), singleton (5)Clade 5 (0)—Clade 6 (0)—Clade 7 (1)Singleton (1)Clade 8 (5)CC184 (1), singleton (4)Clade 9 (5)Singleton (5)Clade 10 (2)CC14 (2)Clade 11 (1)CC5 (1)Clade 12 (3)CC6 (3)Clade 13 (0)—Clade 14 (7)CC15 (1), CC29 (1), CC104 (2), CC211 (2), singleton (1)Clade 15 (2)CC209 (1), singleton (1)Clade 16 (23)CC11 (16), singleton (7)Clade 17 (20)CC12 (8), CC52 (5), CC212 (1), singleton (6)Clade 18 (9)CC10 (4), singleton (5)Singlets (11)CC90 (1), singleton (10) Correlation between UPGMA grouping and eBURST clustering of C. albicans isolates. Distribution of Fluconazole Tolerance and Virulence Phenotypes Across MLST Clades The distribution of FoG20 values across major MLST clades (clades with n > 5) is shown in Figure 4. Clade 14 (median FoG20: 0.44) and clade 16 (median FoG20: 0.42) exhibited the highest median tolerance values, whereas clade 17 exhibited the lowest (median FoG20: 0.16). Because clades 14 (n = 7) and 18 (n = 9) contained relatively few isolates, they were retained for descriptive presentation but excluded from formal inferential comparisons. Among the five adequately represented clades (clades 1, 3, 4, 16 and 17; each n ≥ 20), FoG20 distributions differed significantly (p = 0.031). Post hoc pairwise comparisons with Holm adjustment showed significantly higher FoG20 in clade 16 than in clade 1 (adjusted p = 0.020) and clade 3 (adjusted p = 0.048), whereas differences between clade 16 and clades 4 and 17 were not statistically significant. Distribution of fluconazole tolerance in different clades (n > 5). Distribution of fluconazole tolerance (FoG20) across major Candida albicans MLST clades. Box plots show the distribution of FoG20 values among the isolates belonging to clades with more than five representatives. The horizontal line within each box represents the median, the lower and upper boundaries of the box represent the first (Q1) and third (Q3) quartiles, respectively, and the whiskers extend to the minimum and maximum values. Individual isolates are overlaid as jittered data points. Formal statistical analysis was restricted to the five adequately represented clades (clades 1, 3, 4, 16 and 17; each n ≥ 20), among which FoG20 distributions differed significantly (Kruskal–Wallis test, p = 0.031). * indicates a significant difference in post hoc pairwise comparisons. The distribution of virulence‐associated phenotypes across MLST clades, visualized as a heatmap, revealed notable heterogeneity (Figure 5). Consistent with the FoG20 analysis shown in Figure 4, clade 16 exhibited relatively high fluconazole tolerance. However, among the five adequately represented clades (clades 1, 3, 4, 16 and 17), no significant overall differences were observed for biofilm biomass, protease activity, phospholipase activity ratio, esterase activity, hemolytic activity or DNase activity (all p > 0.05). In a separate focused comparison of clade 16 versus all non‐clade 16 isolates, clade 16 was also associated with higher FoG20 (mean: 0.39) (p = 0.003) and significantly greater biofilm biomass (mean: 0.83) (p = 0.039), whereas the higher prevalence of protease activity did not reach statistical significance (43.5%, p = 0.063). In the multivariable model, clade 16 (Adjusted OR [aOR] 2.86; 95% CI 1.08–7.56; p = 0.034) and protease (aOR 2.65; 95% CI 1.24–5.64; p = 0.012) were independently associated with high tolerance. Biofilm biomass was not significantly associated with high tolerance (aOR 2.11; 95% CI 0.78–5.73; p = 0.142) (Table 3). Distribution of virulence‐associated phenotypes among Candida albicans MLST clades. Heatmap showing the percentage of isolates exhibiting selected virulence‐associated phenotypes across major MLST clades (n > 5) of C. albicans . Fluconazole tolerance (FoG20) and biofilm biomass measured by crystal violet staining (OD590) are presented as the mean proportional values within each clade. Protease, esterase, hemolytic activity, and DNase are presented as prevalence (%), whereas phospholipase activity is presented as the mean precipitation‐zone ratio. Values are displayed within each cell, and colour intensity reflects the magnitude of the corresponding measurement. Phospholipase values represent the precipitation zone ratio, where lower values indicate higher activity. Clades 14 (n = 7) and 18 (n = 9) are displayed for descriptive purposes only because of their limited sample sizes and were excluded from formal inferential comparisons. Statistical comparisons were restricted to the five adequately represented clades (clades 1, 3, 4, 16, and 17; each n ≥ 20). Significant post hoc pairwise comparisons are indicated by a significance marker (*). TABLE 3Univariable and multivariable analysis of factors associated with high fluconazole tolerance.VariablesUnivariable analysisMultivariable analysisOR (95% CI) p aOR (95% CI) p Protease2.75 (1.33–5.69)0.0062.65 (1.24–5.64)0.012Phospholipase activity ratio0.91 (0.06–13.29)0.943Esterase0.86 (0.39–1.90)0.704DNase1.68 (0.82–3.45)0.160Hemolysis (β)1.97 (0.94–4.13)0.071Biofilm biomass2.59 (1.02–6.54)0.0452.11 (0.78–5.73)0.142Clade 163.85 (1.55–9.56)0.0042.86 (1.08–7.56)0.034Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. Univariable and multivariable analysis of factors associated with high fluconazole tolerance. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. The minimum spanning tree of the 179 isolates (Figure 6) revealed that the isolates with the highest tolerance levels (FoG20 Q4) clustered primarily within CC11 (50% [8/16] vs. 20.2% [33/163, non‐CC11]; p = 0.012). A similar trend was observed in CC12, in which 4 of 8 isolates (50.0%) belonged to FoG20 Q4; however, this difference was not statistically significant (p = 0.082), likely owing to the small sample size. Isolates from other CCs showed a more heterogeneous distribution of the FoG20 quartiles. Given the highly diverse population structure consisting of 169 unique DSTs and a high frequency of singletons, high fluconazole tolerance was identified across multiple evolutionarily distinct backgrounds (including clades 1, 4, 14 and 16). While this widespread scattering indicates that tolerance can emerge independently of specific phylogenies, a statistically significant localized enrichment remains evident within clade 16/CC11. Minimum spanning tree of 179 Candida albicans isolates based on MLST profiles and fluconazole tolerance. Minimum spanning tree showing the genetic relationships among C. albicans isolates based on MLST profiles. Each node represents a diploid sequence type (DST), and links indicate genetic relatedness based on allelic differences across the seven MLST loci. Isolates belonging to the same clonal complex (CC) are highlighted in grey, with text labels shown only for CCs containing three or more isolates. Fluconazole tolerance (FoG20) values were categorized into quartiles and mapped onto the corresponding nodes to visualize the distribution of tolerance levels across different MLST genotypes and CCs. Clinical Outcome Analysis The proportion of high fluconazole tolerance (FoG20 Q4) in the persistent candidemia group was not significantly different from that in the non‐persistent candidemia group (45.5% vs. 21.5%, p = 0.068) (Table S3). However, after adjusting for potential clinical confounders, patients infected with high tolerance isolates exhibited a trend toward higher 14‐day crude mortality, with a borderline statistical significance (aOR: 2.56, 95% CI: 0.99–6.62; p = 0.052) (Table 4). TABLE 4Univariable and multivariable analysis of factors associated with 14‐day mortality in patients with candidemia.VariablesUnivariable analysisMultivariable analysisOR (95% CI) p aOR (95% CI) p DemographicsAge (per year)1.01 (0.99–1.03)0.490Male0.91 (0.64–1.79)0.790ICU admission1.64 (0.84–3.20)0.144Immunosuppression2.23 (1.07–4.62)0.0323.56 (1.34–9.41)0.011Candida colonization within 3 months0.99 (0.50–1.94)0.968Prior azoles exposure within 30 days0.79 (0.15–4.03)0.771ComorbiditiesCardiovascular disease0.48 (0.20–1.12)0.089Chronic pulmonary disease0.89 (0.23–3.49)0.862Diabetes1.07 (0.52–2.21)0.852Chronic liver disease1.36 (0.43–4.28)0.601Chronic renal disease0.34 (0.07–1.57)0.166CCI ≥ 51.51 (0.77–2.94)0.231Clinical severitySOFA score ≥ 87.51 (3.46–16.31)< 0.00112.49 (4.84–32.25)< 0.001Septic shock5.02 (2.19–11.51)< 0.001——Neutropenia1.02 (0.25–4.12)0.976Source of bloodstream infectionPrimary2.08 (0.77–5.62)0.150Intravascular catheter‐related0.25 (0.12–0.54)< 0.0010.19 (0.07–0.52)0.001Abdominal3.09 (1.42–6.73)0.004——Urinary tract1.39 (0.63–3.09)0.416Others* 0.67 (0.13–3.33)0.621Fluconazole MIC value (mg/L)0.21 (0.002–22.58)0.511FoG20 Q4 quartile2.27 (1.08–4.79)0.0312.56 (0.99–6.62)0.052Treatment strategyEmpirical therapy a 1.26 (0.65–2.45)0.496Fluconazole daily dose (mg) (per mg/day)0.99 (0.99–1.00)0.247Fluconazole dose/MIC ≥ 4001.27 (0.13–12.49)0.839CVC removal b 0.30 (0.15–0.59)0.0010.38 (0.16–0.92)0.032Source control other than CVC removal c 0.48 (0.23–1.02)0.056Abbreviations: CCI, Charlson comorbidity index; CVC, central venous catheter; ICU, intensive care unit; SD, standard deviation; SOFA, sequential organ failure assessment. a n = 71 (fluconazole [n = 67], echinocandin [n = 4]). b n = 74 (cases with intravascular catheter‐related candidemia). c n = 95 (cases with primary, abdominal, urinary tract and others related candidemia).*Other sources: endocarditis (2), soft tissue/osteomyelitis (2), oropharyngeal/oesophageal candidiasis (2) or 2 sources (3), including intravascular catheter‐related/abdominal (2), and intravascular catheter‐related/urinary tract (1). Univariable and multivariable analysis of factors associated with 14‐day mortality in patients with candidemia. Abbreviations: CCI, Charlson comorbidity index; CVC, central venous catheter; ICU, intensive care unit; SD, standard deviation; SOFA, sequential organ failure assessment. n = 71 (fluconazole [n = 67], echinocandin [n = 4]). n = 74 (cases with intravascular catheter‐related candidemia). n = 95 (cases with primary, abdominal, urinary tract and others related candidemia). Other sources: endocarditis (2), soft tissue/osteomyelitis (2), oropharyngeal/oesophageal candidiasis (2) or 2 sources (3), including intravascular catheter‐related/abdominal (2), and intravascular catheter‐related/urinary tract (1). Discussion In the present study, we examined the relationships among MLST genotypes, fluconazole tolerance, and virulence‐associated phenotypes in C. albicans bloodstream isolates. A prominent fluconazole tolerance phenotype was observed despite the overall susceptibility to fluconazole, highlighting the frequent occurrence of antifungal tolerance in clinical isolates. Higher tolerance levels were weakly but significantly associated with increased biofilm formation and a higher prevalence of protease activity. MLST analysis revealed a genetically diverse population structure dominated by clades 1, 3 and 4. Although tolerance phenotypes were distributed across multiple genetic backgrounds, isolates belonging to clade 16 tended to exhibit higher FoG20 levels and greater biofilm‐forming capacity, with the majority of clade 16 isolates assigned to CC11. To our knowledge, this is the first study to investigate the relationship between MLST population structure and fluconazole tolerance metrics in C. albicans isolates. It is worth noting that, despite decades of research on C. albicans population genetics, the relationship between MLST‐defined genetic background and fluconazole tolerance specifically (as distinct from resistance) has remained largely unexplored until now. This likely reflects two factors. First, prior population‐genetic studies of C. albicans have predominantly focused on the relationship between MLST clades and classical resistance or geographic/epidemiological distribution [16, 17, 18, 21, 23], since routine 24‐h susceptibility testing does not capture the tolerance phenotype. However, quantitative tools capable of systematically measuring tolerance, such as the FoG‐based diskImageR pipeline, have only become widely available over the past decade [6, 7]. Second, unlike resistance, which is often driven by a relatively small number of well‐characterized, high‐effect genetic alterations, tolerance is increasingly understood to arise from multifactorial, quantitative stress‐adaptation programs that do not map cleanly onto a single locus or simple genotype–phenotype relationship [7, 8], potentially explaining why a clear, generalizable link between specific lineages and tolerance has not previously been established. Future studies integrating MLST or whole‐genome sequencing (WGS) with transcriptomic or functional analyses are needed to clarify the molecular basis of tolerance and its contribution to clinical outcomes. Both fluconazole tolerance and biofilm biomass phenotypes may be co‐regulated by shared upstream stress response pathways, notably the calcineurin‐Crz1 axis and Hsp90‐dependent signalling, which govern both biofilm‐associated drug tolerance and broader cellular stress adaptation in C. albicans [8, 38, 39]. However, this correlation was weak (r = 0.218, r 2 ≈0.047), and biofilm biomass was not independently associated with high tolerance in multivariable analysis (Table 3). Therefore, direct experimental evidence linking these shared pathways to the specific phenotypic correlations observed here is lacking and warrants functional validation. In addition to biofilm formation, protease activity was more frequently observed among the highly tolerant isolates in our dataset, raising the possibility that tolerance may be associated with broader stress‐adaptive phenotypes involving both virulence regulation and antifungal survival [29]. Sap5 and Sap6, hyphal‐phase secreted aspartyl proteinases, have been shown to be upregulated during C. albicans biofilm formation and required for proper biofilm development, and C. albicans biofilms have been reported to secrete more aspartyl proteinases than planktonic cells [40, 41]. The co‐occurrence of protease activity and tolerance in highly tolerant isolates may reflect a shared, biofilm‐associated adaptive state. However, this interpretation remains hypothetical and requires mechanistic validation. MLST is a well‐established tool for investigating the population structure, genetic diversity, and global epidemiology of C. albicans [34]. Regional MLST studies of C. albicans bloodstream and other clinical isolates across Asia have consistently identified clades 1, 4 and 17 as the predominant lineages, broadly consistent with the global distribution, in which clade 1 is the most common lineage worldwide and clades 4 and 17 are relatively enriched in Asia compared with other continents [16, 22, 36]. A study from a tertiary hospital in northern Taiwan similarly reported clades 1, 4, 3 and 17 as the dominant lineages among 285 bloodstream isolates, and a study from Thailand reported a predominance of clade 17 among bloodstream isolates, with clade 17 accounting for a substantially higher proportion than reported in non‐Asian cohorts [16, 17]. Notably, none of these regional studies reported a comparably high prevalence of clade 16, which more typically accounts for a small minority of isolates in global collections [16, 17, 22, 36]. The relatively high prevalence of clade 16 in the present cohort (23/179, 12.8%), together with its predominant assignment to CC11, therefore appears distinctive relative to other reported Asian C. albicans populations and may reflect a localized clonal expansion within hospitals in southern Taiwan, rather than a broader regional pattern. This observation underscores the value of continued molecular surveillance across different regions and healthcare networks in Taiwan and neighbouring countries to determine whether clade 16/CC11 enrichment represents an emerging, geographically confined lineage. Although fluconazole tolerance was observed across diverse MLST backgrounds, certain genetic lineages may harbour a higher proportion of tolerant isolates (Figure 6). In particular, isolates belonging to clade 16 showed relatively higher FoG20 values and greater biofilm‐forming capacity, and most clade 16 isolates were assigned to CC11 (Figure 5, Table 2). The broad distribution of high tolerance across multiple unrelated MLST clades strongly supports a model of convergent phenotypic adaptation rather than a lineage‐exclusive evolutionary trait. In C. albicans , fluconazole tolerance likely represents a plastic adaptation driven by shared upstream stress‐response networks (e.g., calcineurin or Hsp90 pathways) independently selected under antifungal pressure. Rather than possessing an exclusive mechanism, clade 16/CC11 may simply exhibit a lower genetic or epistatic threshold that renders this tolerant state more favourable locally. Future WGS studies may identify the potential phylogenetic‐corrected genomic determinants or convergent mutations driving this phenotype. In the current study, high fluconazole tolerance demonstrated a trend toward increased 14‐day mortality (p = 0.052) (Table 4), aligning with prior reports linking elevated tolerance to adverse azole outcomes [6, 7]. However, it showed no association with persistent candidemia. This discrepancy with our previous findings likely stems from fundamental assay differences: while liquid broth microdilution captures planktonic subpopulation survival across concentration gradients [2], disk diffusion‐based FoG20 quantifies colony‐forming tolerance within a spatial inhibition zone gradient, where developing microcolonies experience attenuated drug diffusion that creates microenvironments distinct from in vivo planktonic conditions [7, 8]. Thus, these two assays reflect complementary rather than equivalent dimensions of tolerance. Given our retrospective design and the borderline mortality signal, these findings warrant cautious interpretation and prospective validation in larger cohorts. This study has some limitations. First, the isolates were collected from hospitals in a single geographic region in southern Taiwan, which may limit the generalizability of our findings. Second, isolates were derived from a cohort restricted to patients receiving fluconazole monotherapy for ≥ 48 h, in order to link tolerance phenotypes to actual clinical fluconazole exposure. This inclusion criterion means our findings reflect a clinically selected subgroup rather than an unselected sample of all candidemia episodes, and may not fully generalize to patients treated with echinocandins or combination therapy, who were not represented in this cohort. Third, several MLST clades were represented by small numbers of isolates (e.g., clade 14, n = 7; clade 18, n = 9), limiting the statistical power of between‐clade comparisons for virulence phenotypes that were more variably distributed (protease, hemolytic and DNase activities); these clade‐specific findings should be considered exploratory. Fourth, biofilm formation was quantified using crystal violet staining, which measures total biomass but not metabolic activity. XTT/MTT assays were not performed, and future studies incorporating metabolic viability measures would provide a more complete characterization of this relationship. Fifth, we did not assess classic resistance‐associated pathways, such as ERG11, TAC1 or MRR1 mutations and CDR1/CDR2/MDR1 efflux pump expression. While genetic resistance and phenotypic tolerance are mechanistically distinct in C. albicans [8, 12], regulatory overlaps exist under active drug pressure. However, since 99.4% (178/179) of our clinical isolates were fluconazole‐susceptible (MIC ≤ 2 mg/L), classical resistance mechanisms are unlikely to be the primary driver of the tolerance phenotype observed here and molecular resistance screening was outside our epidemiological scope. Additionally, the associations we observed between fluconazole tolerance and virulence‐related phenotypes were based on in vitro phenotypic assays without genetic or molecular validation. Future studies incorporating WGS and transcriptomic profiling are needed to identify the specific genes and regulatory pathways responsible for the phenotypic associations reported here, and to establish whether these relationships are causal rather than correlative. Finally, MLST provides limited genetic resolution compared to WGS, which may underestimate the true degree of genetic diversity within clades. In conclusion, this study provides the MLST population structure, quantitative fluconazole tolerance, and virulence phenotypes of C. albicans bloodstream isolates in Taiwan. Our data demonstrate that the high‐tolerance phenotype is broadly distributed across evolutionarily distinct and unrelated backgrounds, strongly supporting a model of convergent adaptation rather than lineage‐exclusive genetic hardwiring. Nevertheless, a statistically significant localized enrichment of this high‐tolerance phenotype remains evident within the regional clade 16/CC11 population. Further prospective studies pairing genomic and phenotypic characterizations are warranted to substantiate these findings. Author Contributions Yi‐Ting Tseng: data curation, formal analysis. Shang‐Yi Lin: conceptualization, methodology, formal analysis, investigation, writing – original draft, writing – review and editing. Ho‐Yin Huang: writing – review and editing, data curation. Po‐Liang Lu: conceptualization, writing – review and editing, methodology, formal analysis, supervision. Wei‐Chun Hung: writing – review and editing. Yin‐Tse Huang: writing – review and editing, data curation. Funding This study was supported by research grants from the Ministry of Science and Technology, Taiwan (NSTC 114‐2314‐B‐037‐085‐MY2), the Kaohsiung Medical University Hospital Research Program (KMUH114‐4R26), and the Kaohsiung Medical University Research Program (KMU‐TB114001‐2). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Profile of fluconazole susceptibility, tolerance, and MLST profiles for 179 Candida albicans clinical isolates. Table S2: eBURST clonal distribution of C. albicans isolates. Table S3: Characteristics of patients with persistent and non‐persistent candidemia.